Stocks
Heron Therapeutics Financial Statements (HRTX) |
||||||||||
| Heron Therapeuticssmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 11.05.2023 | 14.08.2023 | 30.09.2023 | 12.03.2024 | 07.05.2024 | 07.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 29.6 | 31.8 | 31.4 | 34.2 | 34.7 | 132.1 | |||
| Operating Income, bln rub | -33.1 | -42.4 | -24.9 | -10.2 | -4.80 | -82.4 | ||||
| EBITDA, bln rub | ? | -32.3 | -41.7 | -24.2 | -9.51 | -4.11 | -79.5 | |||
| Net profit, bln rub | ? | -32.5 | -42.1 | -25.0 | -10.7 | -3.16 | -81.0 | |||
| OCF, bln rub | ? | -24.9 | -27.2 | -9.18 | 2.46 | -9.52 | -43.4 | |||
| CAPEX, bln rub | ? | 0.224 | 0.278 | 0.793 | 0.250 | 0.000 | 1.32 | |||
| FCF, bln rub | ? | -25.1 | -27.4 | -9.97 | 2.21 | -9.52 | -44.7 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 45.8 | 54.0 | 38.2 | 34.6 | 31.0 | 157.8 | ||||
| Cost of production, bln rub | 16.9 | 20.2 | 18.2 | 9.89 | 8.44 | 56.7 | ||||
| R&D, bln rub | 13.8 | 17.6 | 13.6 | 11.0 | 4.61 | 46.7 | ||||
| Interest expenses, bln rub | 0.295 | 0.563 | 0.563 | 2.17 | 0.000 | 3.29 | ||||
| Assets, bln rub | 220.9 | 201.2 | 229.2 | 222.5 | 217.9 | 217.9 | ||||
| Net Assets, bln rub | ? | -11.4 | -39.3 | -27.8 | -34.0 | -33.8 | -33.8 | |||
| Debt, bln rub | 156.9 | 156.1 | 180.0 | 179.6 | 179.2 | 179.2 | ||||
| Cash, bln rub | 60.0 | 33.2 | 77.4 | 80.4 | 71.5 | 71.5 | ||||
| Net debt, bln rub | 96.9 | 122.9 | 102.6 | 99.2 | 107.6 | 107.6 | ||||
| Ordinary share price, rub | 1.51 | 1.16 | 1.03 | 1.70 | 2.77 | 0.670 | ||||
| Number of ordinary shares, mln | 119.2 | 119.7 | 145.0 | 150.3 | 151.2 | 151.2 | ||||
| Market cap, bln rub | 180 | 139 | 149 | 255 | 419 | 101 | ||||
| EV, bln rub | ? | 277 | 262 | 252 | 355 | 526 | 209 | |||
| Book value, bln rub | -11 | -39 | -28 | -34 | -34 | -34 | ||||
| EPS, rub | ? | -0.27 | -0.35 | -0.17 | -0.07 | -0.02 | -0.54 | |||
| FCF/share, rub | -0.21 | -0.23 | -0.07 | 0.01 | -0.06 | -0.30 | ||||
| BV/share, rub | -0.10 | -0.33 | -0.19 | -0.23 | -0.22 | -0.22 | ||||
| EBITDA margin, % | ? | -109.2% | -131.2% | -77.0% | -27.8% | -11.9% | -60.2% | |||
| Net margin, % | ? | -109.7% | -132.4% | -79.6% | -31.3% | -9.11% | -61.3% | |||
| FCF yield, % | ? | -71.6% | -91.9% | -67.3% | -23.6% | -10.7% | -44.2% | |||
| ROE, % | ? | 1 442% | 365.7% | 456.2% | 324.6% | 239.7% | 239.7% | |||
| ROA, % | ? | -74.6% | -71.4% | -55.3% | -49.6% | -37.2% | -37.2% | |||
| P/E | ? | -1.09 | -0.97 | -1.18 | -2.32 | -5.17 | -1.25 | |||
| P/FCF | -1.40 | -1.09 | -1.49 | -4.23 | -9.36 | -2.26 | ||||
| P/S | ? | 1.58 | 1.18 | 1.22 | 2.01 | 3.17 | 0.77 | |||
| P/BV | ? | -15.8 | -3.54 | -5.37 | -7.52 | -12.4 | -3.00 | |||
| EV/EBITDA | ? | -1.94 | -1.93 | -2.12 | -3.29 | -6.62 | -2.63 | |||
| Debt/EBITDA | -0.68 | -0.91 | -0.87 | -0.92 | -1.35 | -1.35 | ||||
| R&D/CAPEX, % | 6 168% | 6 321% | 1 710% | 4 380% | 3 534% | |||||
| CAPEX/Revenue, % | 0.76% | 0.88% | 2.52% | 0.73% | 0.00% | 1.00% | ||||
| Heron Therapeutics shareholders | ||||||||||
